Key Highlights

  • Revenue was USD 642,889 versus USD 2,167 a year earlier.
  • Gross profit reached USD 536,266 on cost of revenues of USD 106,623.
  • Net loss narrowed to USD 1.9 million from USD 2.9 million.
  • Cash and cash equivalents stood at USD 660,916 on September 30, 2026.

Revenue Appears After a Near-Zero Base

Ainos, Inc. (NASDAQ:AIMD) reported third-quarter Revenue of USD 642,889 compared with USD 2,167 in the prior-year quarter, and nine-month revenue of USD 643,202 versus USD 113,037. Cost of revenues was USD 106,623 for the quarter, leaving Gross Profit of USD 536,266 versus USD 1,690.

The company was incorporated in Texas in 1984 and describes itself as a dual-platform company developing "artificial intelligence-enabled olfactory sensing technologies" connected to what it calls Chemical Intelligence, alongside a second development platform.

The company states that the quarter's revenue followed a period in which it reported only small amounts, so the year-over-year comparison starts from a minimal base.

Operating Expenses and Loss

Total operating expenses were USD 2,220,938 versus USD 2,785,883, with selling, general and administrative expense of USD 524,919 versus USD 795,253. The remainder was research and development, part of which was paid to a related party. Loss from operations was USD 1,684,672 versus USD 2,784,193.

Interest expense was USD 204,763 versus USD 176,584, and total non-operating expenses, net, were USD 201,402 versus USD 147,509. Net loss was USD 1,886,074 versus USD 2,931,702.

Operating expenses for the nine months were weighted toward research and development, which included amounts paid to a related party of USD 681,437 for the nine months and USD 231,867 for the quarter. Other income, net, was USD 3,361 for the quarter versus USD 29,075.

Nine-Month Results and Liquidity

For the nine months, total operating expenses were USD 8,903,168 versus USD 9,786,141, selling, general and administrative expense was USD 3,666,880 versus USD 4,159,627 and loss from operations was USD 8,367,405 versus USD 9,692,751. Interest expense was USD 581,801 versus USD 534,986, and net loss was USD 8,940,605 versus USD 10,302,714.

At September 30, 2026, the company had available cash and cash equivalents of USD 660,916, which sits against quarterly operating expenses above USD 2.2 million.

Nine-month revenue of USD 643,202 compares with USD 113,037, and cost of revenues was USD 107,439 versus USD 19,647, giving nine-month gross profit of USD 535,763 versus USD 93,390. Net loss before income taxes equaled net loss in both periods, so the filing shows no income tax line. Other income, net, was USD 8,601 for the nine months versus other expense of USD 74,977, and total non-operating expenses, net, were USD 573,200 versus USD 609,963.

Signposts for the Fourth Quarter

Reference points include whether revenue recorded in the third quarter recurs, the Gross Profit Margin on those sales, the pace of research spending and the financing steps described in the Liquidity discussion.

The filing lists cash of USD 660,916 against interest-bearing obligations that produced USD 204,763 of quarterly interest expense, which frames the funding discussion.